Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers
Epithelial ovarian tumors are a group of morphologically and genetically heterogeneous neoplasms. Based on differences in clinical phenotype and genetic background, ovarian neoplasms are classified as low-grade and high-grade tumor. Borderline ovarian tumors represent approximately 10%–20% of all ep...
Saved in:
| Main Authors: | Pawel Sadlecki, Pawel Walentowicz, Magdalena Bodnar, Andrzej Marszalek, Marek Grabiec, Malgorzata Walentowicz-Sadlecka |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-05-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317706230 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system
by: Pawel Sadlecki, et al.
Published: (2017-10-01) -
Giant borderline ovarian tumours – review of the literature
by: Sadlecki Pawel, et al.
Published: (2025-08-01) -
Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer
by: Pawel Walentowicz, et al.
Published: (2013-01-01) -
Prospects of BRAF/MEK Inhibitor Therapy in Papillary Craniopharyngiomas with the BRAF V600E Mutation: A Scoping Review
by: Shingo FUJIO, et al.
Published: (2025-05-01) -
Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma☆
by: G.K. In, et al.
Published: (2024-12-01)